Chandresh Sharma; has a post-graduate degree from the Indian Institute of Technology Roorkee, Roorkee, India. He was awarded the PhD degree from, All India Institute of Medical Sciences (AIIMS), New Delhi, in the year 2011, for his contribution towards “Development of HPV16 chimeric candidate vaccine prototype”. This chimeric VLP based vaccine had been successfully tested in a murine model of cervical cancer for its prophylactic and therapeutic efficacy. In his postdoctoral training as Research Associate (2011-2012) at AIIMS, he had designed another chimeric candidate vaccine against HPV18. He received an Innovation Award (2012-2019) for the research project “Development of a rapid test for improved typhoid diagnostics” at CBD, THSTI, Faridabad, India. In his tenure as an Innovation Awardee, his chief contribution has been towards translational research through the generation of specific S. typhi proteins and anti-flagellin murine monoclonal antibodies, for improved typhoid diagnosis, which has also been demonstrated in a proof of concept. He filed two Indian patent applications on point-of-care typhoid diagnosis. Dr. Sharma, as a Research Scientist (2019-2022) at THSTI has demonstrated his translational research capabilities through the generation of novel recombinant gene products, particularly, high-quality diagnostic intermediates; scaffold protein and monoclonal antibodies, targeting various pathogens (Salmonella, HBV, HEV SARS-CoV-2 etc.), for improved diagnosis and accurate therapy.